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H1017136 ACE-1UeeandLVFunctioninthe ElderlyAdmittedwithHeartFailure:GanderDifferences
C.A. Sueta,A. Metts, T.R. Grigga, V.C. Borders, R.J. Simpson, Jr..
University of North Carolina, Chapel Hill, NC, USA, Medical Review of North
Carolina, USA
The charts of 1478 Medicare (age ? 65 yrs) patients (pts) from 48 hospi-
tals in North Carolina with a discharge diagnosis of heart failure (HF) were
retrospeetively reviewad to determine angiotenain converting enzyme in-
hibitor (ACE-1)use and assessment of left ventricular function (LVF). Data
was collected from hospitalizations occurring between 1/1/95 to 9/30/95. Pts
admitted with acute or recent (< 6 wks) myocardial infarction (Ml) were ex-
cluded. The mean age waa 78 + 8 (SD) yra, 59% were women, and 21Y0
were African American. The majority of pts had a hiatory of HF (82%), hyper-
tension (53%), history of Ml (26%) and CABG (157.). During hoapifalization,
a CXR was obtained in 96% of pts and evidence of cardiomegaly or fluid
overload was prasent in 89%. Previous assessment of LVF or assessment
during hospitalization was documented in 51’Yoof pts. During hospitalization,
LVF was assessed more often in men compared to women, 42% vs. 367.,
p = 0.032. The mean LV ejection fraction determined in 465 pta was 39%
+ 17 and was significantly higher in women compared to men, 43% + 17
vs. 34% + 16, p <0.001. Forty percent of discharged pts were not ideal
candidates for ACE-1therapy (ACE-1intolerant, serum creatinine >2, K >
5 mEq/L, LVEF ? 40% or normal by ECHO, or on hydralezine + isordil).
Fifty-three percent of ideal pts were discharged on ACE-1,57% of men vs.
50Y0of women p = 0.052. Length of stay, 5.8+ 4.4 vs. 6.5 + 5.7 days, p =
0.018 and thirty day total mortality ,was significantly lower in the group who
were discharged on ACE-1,4.2% vs. 7.5%, p = 0.01.
Assessment of LVF in Medicare pts admitted with HF occurred less
frequently in women, but systolic function was significantly better compared
to men. Only 53% of ideal candidates were discharged on an ACE-1.There
exists a significant opportunity to impact on the health care of elderly pts
admitted with heart failure.
H1017137 TheUtilityofAngiotenein-ConvertingEnzymeInhibitor inHeartFailureWithPrasarvadLeft
VentricularSyatolicFunction
E.F. Philbin, T.A. Rocco. Massechuseffs General Hospital, Boston, MA,
USA, Park Ridge Health System, Rcchestec NY USA
To better understand the role for angiotensin-converting enzyme inhibitors
(ACEI) in congestive heart failure (CHF) due to diastolic dysfunction, we
screened the records of 1,402 consecutive patients admitted to 10 cen-
ters and identified 763 hospital survivora whose LV function waa assessed.
Patients were followed prospectively for 6 months after discharge; death,
hospital readmission and functional status were tracked. Diastolic heart fail-
ure was defined as clinical CHF with an LV ejection fraction (EF) z 40Y. or
qualitatively normal LV contractility. Outcomes were stratified by ACEI pre-
scription at diacharge and adjusted for differences between the subgroups.
ACEI were prescribed to .5&. of 350 patientawith diastolic failure and 77% of
413 with aystolic failure. The risk-adjuated odda ratios (OR) for death and/or
rehospitalization asacciated with ACEI prescription are shown in the Table:
Endpoint EF > 40% EF s 39”A
OR P OR P
A1l-csussmortality o,6t7 0.12 0,766 0.38
CHF death 0,549 0.13 0,587 0.16
Any rehospitalization 0.978 0.92 0.639 0.08
CHF rehospitalization 0.993 0,9s 0.644 0.11
Dasthorrehospitalization 0.916 0.69 0.552 0.02
ACEI uae waa associated with longer times to firat rehospitalization and
CHF rehospitalization in both groups, but not related to functional atetus
meaaurea in either group. Though limited by small aample size and the
uae of case-control methodology, this study auggests that the magnitude of
banefit from ACEI use in diastolic failure is less than that in systolic diaease,
particularly regarding ratea of hoapital readmission. Future randomized trials
would offer more definitive testing of thia hypothesis.
1017-138 DifferencesinGeneralistandSpecialist
Phyalciana’KnowledgeRegardingUeeofAce
Inhibitor forCongeativaHeartFailura
M.H. Chin, P.D. Friedmann, C.K. Cassel, R.M. Lang. The Univeraityof
Chicago, Chicago, IL, USA
To determine the factors associated with underutilization of angiotensin con-
verting enzyme inhibitors (ACEI) for patients (PTS) with CHF, we surveyed
a national systematic sample of 500 family practitioners (FP), 500 general
internists (lM), and 500 cardiologists (CD) about their choice of medications
in four hypothetical PTS with reduced LV ejection fraction: 1) New-onset of
symptoms (SYMPT); 2) Asymptomatic (ASYMPT); 3) Symptomatic chronic
CHF, on digitalis and diuretics (CHRONIC); and 4) Asymptomatic, poat-
myoeardial infarction (POST-Ml). Among the 727 (55%) eligible physicians
(MDs) returning surveys, about 90% used ACEI in the CHRONIC case. Yet
FP and IM used ACEI less frequently than CD forthe other 3cases: ASYMPT
(FP 68%, IM 78%, CD 93%), POST-Ml (FP 58%, IM 70%, CD 94%), and
SYMPT (FP 72%, IM 76%, CD 86%). In multivariable analyses adjusting
for physician’s gender, region, years in practice, and number of CHF PTS,
correlates of ACEI use for the ASYMPT case were CD (adjusted odds ratio
[OR 5.5, 95% confidence interval [Cl] 2.7-11.2), IM (OR 1.9, Cl 1,1-3.3),
board certification (OR 2.5, Cl 1.4-4.4), and estimated relative risk reduction
(RR) from using ACEI (OR 1.7 per 10% reduction, Cl 1.5-1.9). Correlate for
the POST-Ml case were CD (OR 7.8, Cl 4.4-14.1), estimated absolute RR
(OR 1.7 per 10%, Cl 1A-2.1), and estimated relative RR (OR 0.9 per 10%,
Cl 0.8-1.0), Perceived rates of side effecta from ACEI were not correlated
with use of ACEI in the ASYMPT and POST-Ml cases. Compared to CD,
FP and IM underutilize ACEI, particularly in asymptomatic PTS with CHF.
Number of CHF PTS treated, perceptions of risk reduction, and side effaeta
fail to explain these differences. Educational efforts should foeus on the uae
of ACEI in ASYMPTOMATIC and POST-Ml patients.
11017-1391 FactOralnfluancingUnderutilizationof
AngiotenainConvertingEnzymeInhibitor in
Inpatient WithHeartFailura
J.K. Ghali, S. Kumar, I.C. Sarkar, R. Horewell, G. Livaudais, J.P. Murgo,
T. Giles. Louisiana Health Care Review, Inc., Baton Rouge, La, USA,
Louisiana Chapter of the American Co//ege of Cardio/og~ New Orfeans, Le,
USA
Publiahed guidelines endorse the use of angiotensin converting enzyme
inhibitore (ACEI) in heart failure (HF) patients with impaired left ventricular
systolic function (LVSF). The records of 1133 Medicare acute care patients
discharged alive over a four month period in 1993 were reviewed. Maan
age of study sample was 78 + 6 yeara, 64% were female. Use of ACEI
was documented in 385 cases (34%) on admission. Among the 745 patients
not on ACEI at admission, assessment of LVSF was available in 415 caaes
and missing in 330 cases. of the 330 cases, only 86 cases (26%) were
discharged on ACEl; compared to 174caaes (42%) among the415caseswith
assessment of LVSF (P < 0.0001). Among 626 eases with documentation of
LVSF,a logistic regression model indicated that the following characteristics
decreasad the probability of discharge on ACEI; black race (odda ratio OR,
0.5 p < 0.01) angina (OR, 0.6, p = 0.05), history of Ml or ischemia (OR,
0.5, p = 0.01), history of renal failure (OR, 0.4, p = 0.04) and increasing
creatinine (OR, 0.5, p = 0.05). Characteristics that increased the probability
of discharge as ACEI included; orthopnea (OR, 1.6, p = 0.011), increasing
blood presaure (OR, 1.01, p z 0.05), cam’iomagaly (OR, 1.6, p = 0.06) and
iOW LVEF (OR, 1.8, p = 0.01).
Conclusion.’(1) ACEI are underutilized in hospitalized Medicare HF pa-
tients. (2) Defining LVSF increases the use of ACEI. (3) Underutilization of
ACEI in hospitalized Medicare HF patients appeara to result from factors
perceived to ba associated with unwanted outcomes from ACEI.
I 1017-140/ ACE-inhibitorUtilizationin COngestiveHeat’t
Failure:A Surveyon2343ItalianOutpatients
A.P. Maggioni, D. Lucci, M. Gorfni, G. Perini, C. Opasich, L. Tavazzi, for the
IN-CHF Investigators. ANMCO Research Centec Florence, Italy
Several large scale clinical trials have definitely shown that ACE-inhibitora
(ACE-i) reduce mortality and morbidity of the pta with congestive hearl failure
(CHF). However, pharmacoepidamiologioal observations showed that only
a minority of pts who might benefit from thie treatment are actually treated.
Further, when prescribed, ACE-i ara givan at lower dosages than those
proven to improve survival.
Aima of the study were to evaluate in a large population of Italian outpa-
tients: (a) the rate of uae of ACE-i; (b) the prescribed doaes; (c) the deter-
minants of their utilization. Data were collected by locally trained clinician
using an ad-hoc software.
A total of 2343 pta were evaluated by 80 cardiological centera over a
period of 10 months. 1885 (80%) pta were on treatment with ACE-i; 1647
(70%) ACE-i treated pts were on mmbination with diuretics, 1247 (53%)
with a diuretic and digitalis. In the pts receiving an ACE-i: 39Y0were treated
with enalapril (mean daily doae 14 + 8 mg), 31%.with captopril (mean daily
dose 69 + 42 mg), 15% with Iisinopril (mean daily dose 13 k 8 mg). The
remaining 15% of the pts were treated with a miscellaneous of the other
ACE-i available on the Italian market. The relationship between clinical-
epidemiological variables and ACE-i prescription is shown in the table.
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